Antidepressant ‘shrooms: rebranding psilocybin as medication [W[R]C]
3 de feb. de 2023 ·
13m
![Antidepressant ‘shrooms: rebranding psilocybin as medication [W[R]C]](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_480/images.spreaker.com/original/587b3e525991bbdc4ecbea90ad9ca347.jpg)
Regístrate gratis
Escucha este episodio y muchos más. ¡Disfruta de los mejores podcasts en Spreaker!
Descarga y escucha en cualquier lugar
Descarga tus episodios favoritos y disfrútalos, ¡dondequiera que estés! Regístrate o inicia sesión ahora para acceder a la escucha sin conexión.
Capítulos
Descripción
https://www.biotechniques.com/neuroscience/antidepressant-shrooms-rebranding-psilocybin-as-medication/ Sixtine Fleury is a second-year graduate student in the Nautiyal Lab at Dartmouth College (NH, USA). At this year’s meeting of the Society for Neuroscience (SfN; 12–16 November; San...
mostra más
https://www.biotechniques.com/neuroscience/antidepressant-shrooms-rebranding-psilocybin-as-medication/
Sixtine Fleury is a second-year graduate student in the Nautiyal Lab at Dartmouth College (NH, USA). At this year’s meeting of the Society for Neuroscience (SfN; 12–16 November; San Diego, CA, USA), she presented a poster on altered consciousness and the role of the non-hallucinatory serotonin 1B receptor in psilocybin’s therapeutic effects.
We had the chance to chat to her about her poster and her experience at SfN.
mostra menos
Sixtine Fleury is a second-year graduate student in the Nautiyal Lab at Dartmouth College (NH, USA). At this year’s meeting of the Society for Neuroscience (SfN; 12–16 November; San Diego, CA, USA), she presented a poster on altered consciousness and the role of the non-hallucinatory serotonin 1B receptor in psilocybin’s therapeutic effects.
We had the chance to chat to her about her poster and her experience at SfN.
Información
| Autor | UniquilbriuM |
| Página web | - |
| Etiquetas |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
